FLT3 and acute myeloid leukemia: Cytogenetic markers, including FLT3, NPM1, TP53, CEBPA, IDH, DNMT3A, and KIT mutations, are vital tools for risk stratification in AML, guiding personalized treatment plans and improving patient prognosis [5].